• Explore /
  • Poster
  • / Adverse events (AEs) with maintenance olaparib in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Phase III SOLO1 trial.

Adverse events (AEs) with maintenance olaparib in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Phase III SOLO1 trial.

Abstract Poster

Authors

null

Nicoletta Colombo

University of Milan-Bicocca and Istituto Europeo di Oncologia, Milan, Italy

Nicoletta Colombo , Kathleen N. Moore , Giovanni Scambia , Ana Oaknin , Michael Friedlander , Alla Sergeevna Lisyanskaya , Anne Floquet , Alexandra Leary , Gabe S. Sonke , Charlie Gourley , Susana N. Banerjee , Amit M. Oza , Antonio González-Martín , Carol Aghajanian , William Hampton Bradley , Jae-Weon Kim , Elizabeth S. Lowe , Ralph Bloomfield , Paul Disilvestro

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT01844986

Citation

J Clin Oncol 37, 2019 (suppl; abstr 5539)

DOI

10.1200/JCO.2019.37.15_suppl.5539

Abstract #

5539

Poster Bd #

362

Abstract Disclosures

Similar Posters

First Author: Cara Amanda Mathews

First Author: Michael Friedlander

First Author: Sana Intidhar Labidi-Galy

First Author: Ramez Nassef Eskander